Financial Health Check: Examining Repligen Corp (RGEN)’s Key Ratios

Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.

Repligen Corp (NASDAQ: RGEN) closed the day trading at $124.35 down -1.81% from the previous closing price of $126.64. In other words, the price has decreased by -$1.81 from its previous closing price. On the day, 0.57 million shares were traded. RGEN stock price reached its highest trading level at $128.0 during the session, while it also had its lowest trading level at $124.19.

Ratios:

For a better understanding of RGEN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.87 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 66.03. For the most recent quarter (mrq), Quick Ratio is recorded 7.32 and its Current Ratio is at 8.59. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.32.

On June 24, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $150.

Wolfe Research Upgraded its Peer Perform to Outperform on April 29, 2025, while the target price for the stock was maintained at $160.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 08 ’25 when Madaus Martin D bought 1,800 shares for $112.13 per share. The transaction valued at 201,830 led to the insider holds 1,800 shares of the business.

Hunt Anthony sold 26,447 shares of RGEN for $3,271,688 on May 15 ’25. The Director now owns 109,854 shares after completing the transaction at $123.71 per share. On May 15 ’25, another insider, Hunt Anthony, who serves as the Director of the company, bought 26,447 shares for $128.34 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGEN now has a Market Capitalization of 6995351552 and an Enterprise Value of 6972562432. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.38 while its Price-to-Book (P/B) ratio in mrq is 3.39. Its current Enterprise Value per Revenue stands at 10.346 whereas that against EBITDA is 55.138.

Stock Price History:

The Beta on a monthly basis for RGEN is 1.07, which has changed by -0.19158757 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, RGEN has reached a high of $182.52, while it has fallen to a 52-week low of $102.96. The 50-Day Moving Average of the stock is 1.34%, while the 200-Day Moving Average is calculated to be -10.03%.

Shares Statistics:

Over the past 3-months, RGEN traded about 828.38K shares per day on average, while over the past 10 days, RGEN traded about 771630 shares per day. A total of 56.25M shares are outstanding, with a floating share count of 53.18M. Insiders hold about 5.46% of the company’s shares, while institutions hold 103.15% stake in the company. Shares short for RGEN as of 1753920000 were 3636755 with a Short Ratio of 4.39, compared to 1751241600 on 3765995. Therefore, it implies a Short% of Shares Outstanding of 3636755 and a Short% of Float of 8.72.

Leave a Reply

Your email address will not be published. Required fields are marked *

DWinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.